Cantor Fitzgerald initiated coverage of DBV Technologies (DBVT) with an Overweight rating and $42 price target DBV Technologies is focused on epicutaneous immunotherapy designed to retrain the immune system and reduce severe allergic reactions from accidental exposure. Its lead asset, the VIASKIN peanut patch, is in late-stage development, with Phase 3 VITESSE data expected before year-end 2025, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- DBV Technologies price target raised to $35 from $20 at H.C. Wainwright
- DBV Technologies initiated with an Overweight at Cantor Fitzgerald
- Guggenheim starts DBV Technologies at Buy on peanut allergy market potential
- DBV Technologies initiated with a Buy at Guggenheim
- Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments